Lobbying registration dated 2026-03-05
Registrant: WILLIAM DEMPSTER
Client: AbbVie Corporation
Targeted institutions:
Finance Canada (FIN)
Treasury Board Of Canada Secretariat (TBS)
Prime Minister's Office (PMO)
House of Commons
Innovation, Science and Economic Development Canada (ISED)
Indigenous Services Canada (ISC)
Global Affairs Canada (GAC)
Public Health Agency of Canada (PHAC)
Patented Medicine Prices Review Board (PMPRB)
Privy Council Office (PCO)
Senate of Canada
Health Canada (HC)
Acts: Pharmacare Act
Government funding received:
Lobbying activity details:
Implementation of the National Strategy for Drugs for Rare Diseases and the Pharmacare Act.
Enhancements related to intellectual property legislation, regulations and policies applicable to pharmaceuticals.
Regulations, guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board
Federally-funded Public Drug Plans, with respect to reimbursement for medicines for federal plan beneficiaries.
Issues related to U.S. pharmaceutical importation, trade and policies, including research and development, regulatory authorizations, funding of medicines, supply sources and supply chains.
Enhancement to Canada's regulatory and funding environment for new medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions.
Innovation, Science and Economic Development Canada and Innovation Agenda, Science and Technology Strategy, or other Government policy or program initiatives to support research and development activities and attract investments in Canada, including the Biomanufacturing and Life Sciences Strategy.